NCT01183143View on ClinicalTrials.gov

Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization

PHASE3CompletedINTERVENTIONAL

Enrollment

215

Participants

Timeline

Start Date

May 11, 2004

Primary Completion Date

March 2, 2006

Study Completion Date

March 2, 2006

Conditions

InfertilityOvulation InductionIn-Vitro Fertilization

Interventions

DRUG

GONAL-f®

GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.

Trial Locations (1)

64293

Please Contact the Merck KGaA Communication Center, Darmstadt

All Listed Sponsors

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01183143 - Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization | Biotech Hunter | Biotech Hunter